Omalizumab for Coronavirus (CIAO Trial)

"This investigation is currently not enrolling participants. Initially posted on October 15th 2021, the trial was last updated November 14th 2022. There are presently 1037 clinical trials actively searching for subjects afflicted with covid-19 and 22 studies seeking individuals to test Omalizumab's efficacy."

"Omalizumab is largely prescribed to treat perennial aeroallergen reactivity but can also be beneficial for those who experience asthma-related symptoms that are not adequately managed by inhaled corticosteroids, histamine h1 antagonists, and non-sedating medications."

"Unfortunately, no further participants are being accepted for this particular trial. It was initially posted on 10/15/2021 and last edited 11/14/2022. Fortunately, there is an abundance of other ongoing trials: 1,037 related to Covid-19 and 22 regarding Omalizumab that have vacancies waiting to be filled."

"This medical trial will assess the mortality rate and need for mechanical ventilation of patients over a 29 day period. Secondary outcomes include the amount of individuals requiring breath support, all-cause hospital death rates, and time to clinical improvement as determined by an 8 point ordinal scale (ranging from uninfected with no evidence of infection to death)."

"Omalizumab has been evaluated in Phase 2 trials, implying there is a degree of safety data that exists but no proof yet of its efficacy. Thus, it obtained a score of 2 on our team's scale."

"Currently, 22 experiments on Omalizumab are underway with 6 in the Phase 3 stage. These trials take place at 254 locations around the globe, yet a majority of them occur near Jerez de la Frontera, Cádiz."